

29 May 2025

Cykel AI PLC
("Cykel AI" or the "Company")

Cykel AI Secures Enterprise-Level Commercial Agreement with Transpharmation, Generating New Revenue Stream in Pharmaceutical Sector

Cykel AI PLC (LSE: CYK) is pleased to announce the signing of a commercial agreement with Transpharmation Ltd., a global leader in neuroscience, pain and metabolic disease preclinical contract research. Transpharmation will deploy Lucy, Cykel's AI recruitment agent, across their UK and North American operations, opening a new revenue stream for Cykel in the pharmaceutical research sector. The agreement includes an initial 12-month term with renewal options for Lucy's Enterprise plan.

Coming after Transpharmation's recent acquisition of biomarker technology provider Saretius, this commercial deployment supports Transpharmation's market leadership in pharmaceutical research services. With over 150 employees and sites spanning two continents, Transpharmation has chosen an enterprise subscription to support the expansion of their team and operations.

Dr Mark Duxon PhD, Chief Executive Officer at Transpharmation Ltd, said: "As a company dedicated to advancing therapeutic medicine through cutting-edge research, we recognise the importance of securing the brightest scientific minds. Our investment in Cykel's AI recruitment technology reflects our commitment to innovation not just in our research methodologies, but in how we acquire talent efficiently and cost-effectively. After evaluating multiple options, we selected Lucy for her autonomous recruitment capabilities and alignment with our mission to build world-class research teams while optimising operational expenses."

Transpharmation has subscribed to Cykel's Enterprise plan, which carries the highest subscription value in Cykel's tiered pricing model. This premium subscription provides access to Lucy's full suite of functionalities, including:

- AI-powered search across 300 million professional profiles
- Automated multi-channel outreach
- Integration with ATS systems
- Advanced AI screening and talent matching
- Customisation options tailored to Transpharmation's requirements
- Unlimited workspace capacity to support their global operations

With the global pharmaceutical market valued at £1.25 trillion in 2023, this agreement underscores Lucy's commercial value proposition in this high-growth segment and marks a step forward in Cykel's ability to monetise its technology in regulated, knowledge-intensive industries.

Ewan Collinge, CEO & Founder of Cykel AI, commented: "Securing Transpharmation as a customer endorses our commercial strategy and product-market fit in knowledge-intensive sectors. This agreement not only generates revenue but establishes a foundation for expanded commercial opportunities as Transpharmation explores additional digital workers in their operations. The enterprise-level contract reflects the scalability of our pricing model and our ability to convert market-leading companies into customers."

This agreement follows Cykel's recent announcement of paid subscription growth for Lucy across all tiers, including Starter, Pro and Enterprise.

For further information, please contact: investors@cykel.ai

About Transpharmation Ltd

Transpharmation Ltd is at the forefront of neuroscience and related research, specialising in

Transpharmation Ltd. is at the forefront of neuroscience and related research, specialising in translational pharmacology, and drug discovery services. With sites in North America and Europe, together with over 150 employees, Transpharmation has built a reputation for providing tailor-made screening and disease models for the human pharma, biotech and animal health industries. Transpharmation is dedicated to playing its part in the development of impactful therapeutic medicines for animals and humans.

<https://www.transpharmation.com>

About Cykel AI

Cykel AI creates autonomous digital workers that perform complex business tasks without human supervision. The Company's expanding portfolio includes Lucy (recruitment), Samson (research analysis), and Eve (sales), all built on TaskOS - Cykel's proprietary AI agent infrastructure. Cykel's digital workers operate alongside human teams, enabling businesses of all sizes to transform their operations at scale while delivering measurable ROI.

www.cykel.ai

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRASESFWAEISESI